(Q33345428)

26 July 2017

Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group (English)

1 reference

Eastern Cooperative Oncology Group

26 July 2017

phase II clinical trial

0 references

author

6

object named as

Eastern Cooperative Oncology Group

1 reference

26 July 2017

5

George Wilding

1 reference

26 July 2017

Bruce J Roth

1

1 reference

26 July 2017

Judith Manola

2

1 reference

26 July 2017

Robert Dreicer

3

1 reference

26 July 2017

David Graham

4

1 reference

26 July 2017

1 November 2002

1 reference

Investigational New Drugs

26 July 2017

1 reference

26 July 2017

20

1 reference

26 July 2017

425-429

1 reference

26 July 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1020675017737

26 July 2017

0 references

cites work

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma.

1 reference

12 December 2020

Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen

1 reference

12 December 2020

Biochemical and chemotherapeutic studies on 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine (BW 301U), a novel lipid-soluble inhibitor of dihydrofolate reductase

1 reference

12 December 2020

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

12 December 2020

Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies

1 reference

12 December 2020

A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U).

1 reference

12 December 2020

Metabolic inhibition by a new antifolate, 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methyl-pyrido[2,3-d]pyrimidine (BW3O1U), an effective inhibitor of human lymphoid and dihydrofolate reductase-overproducing mouse cell lines.

1 reference

12 December 2020

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder

1 reference

12 December 2020

Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world

1 reference

12 December 2020

Oral piritrexim, an effective treatment for metastatic urothelial cancer

1 reference

12 December 2020

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

1 reference

12 December 2020

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

12 December 2020

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration

1 reference

12 December 2020

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

12 December 2020

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

12 December 2020

Oral piritrexim in advanced bladder cancer: an effective drug after progression on MVAC chemotherapy?

1 reference

12 December 2020

Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1020675017737

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference